Drug-Coated Balloon Catheter Market By Product Type (Paclitaxel-Coated Balloon Catheters, Sirolimus-Coated Balloon Catheters); By Application (Peripheral Artery Disease, Coronary In-Stent Restenosis, Small-Vessel Coronary Disease, De Novo Coronary Lesions, Below-the-Knee Artery Disease, Arteriovenous Fistula Stenosis); By End User (Hospitals, Cardiac Catheterization Laboratories, Vascular Intervention Centres, Ambulatory Surgical Centres, Office-Based Laboratories); By Geography, Segment Revenue and Volume Estimation, Forecast, 2026–2032

Drug-Coated Balloon Catheter Market: Coronary Approval, Peripheral Durability and Sirolimus Competition Reshape Vascular Intervention

The Global Drug-Coated Balloon Catheter Market was valued at USD 1.30 billion in 2025 and is projected to reach USD 2.65 billion by 2032, expanding at a CAGR of 10.8% during the forecast period.

 

Government statistics reinforce the clinical demand base behind this market. The U.S. Centers for Disease Control and Prevention estimates that approximately 6.5 million people aged 40 years and older in the United States have peripheral artery disease. The U.S. FDA also reported that patients treated with the AGENT DCB experienced an 11.1% reduction at 12 months in the combined occurrence of heart attack, death and the need for a repeat procedure compared with patients treated with uncoated balloon catheters. These figures connect the market opportunity to a large vascular-disease population and measurable reductions in repeat treatment.

 

Drug-coated balloons deliver an antiproliferative drug directly into the vessel wall during a short balloon inflation, treating arterial narrowing without leaving a permanent metal stent behind. The market primarily relies on two drug platforms: paclitaxel-coated balloons and sirolimus-coated balloons. Paclitaxel currently supports the larger commercial base, while sirolimus is becoming the principal focus of new product development and clinical investment.

 

Established paclitaxel-coated balloon portfolios include Boston Scientific’s AGENT DCB for coronary in-stent restenosis, Medtronic’s IN.PACT Admiral for femoropopliteal peripheral artery disease and SurVeil for peripheral artery intervention. Paclitaxel is commercially established because it transfers rapidly into the vessel wall, limits the tissue growth responsible for restenosis and is supported by extensive regulatory approvals, physician experience and long-term clinical evidence.

 

Sirolimus-coated platforms include Concept Medical’s MagicTouch portfolio and MedAlliance’s SELUTION SLR. These products are designed to control excessive cell growth after angioplasty while supporting vessel healing and avoiding another permanent implant. Their commercial potential depends on delivery technologies that retain the drug in the vessel wall for longer after the balloon is removed.

 

The development pipeline is increasingly focused on improved sirolimus delivery, stronger tissue retention and expansion into coronary small-vessel disease, arteriovenous fistulas and below-the-knee peripheral disease. Orchestra BioMed’s Virtue sirolimus-eluting balloon, Concept Medical’s MagicTouch SV and MagicTouch AVF programs, and the SirPAD clinical program represent important development routes. These platforms are intended to overcome limitations associated with short drug-contact time, coating loss and treatment of smaller or more complex vessels.

 

Paclitaxel-coated balloons retain the largest installed base because they have established regulatory approvals, extensive peripheral evidence and broad physician familiarity. Sirolimus-coated platforms are creating a second competitive route built around controlled drug release, vessel healing and potential expansion into coronary, femoropopliteal and below-the-knee disease.

 

Hospitals, cardiac catheterization laboratories, vascular centers and ambulatory intervention facilities represent the principal end users because they manage vessel preparation, imaging, balloon delivery, bailout stenting, antiplatelet therapy and repeat-intervention monitoring. The market therefore extends beyond the coated balloon itself to include the procedural ecosystem required for successful drug transfer.

 

Peripheral Drug-Coated Balloons Preserve the Commercial Base

Peripheral drug-coated balloons represented approximately 71.4% of global market revenue in 2025. Applying this share directionally to the USD 1.2 billion market produces an estimated peripheral DCB revenue allocation of approximately USD 856.8 million in 2025 and USD 1.50 billion by 2032, assuming the segment expands in line with the overall 8.3% market CAGR.

Peripheral artery disease affects approximately 6.5 million adults aged 40 years and older in the United States. Only a portion of this population undergoes endovascular intervention, but progressive symptoms, chronic limb-threatening ischemia, restenosis and long femoropopliteal lesions create a recurring procedural demand pool.

Peripheral DCBs are commercially attractive in arteries exposed to bending, compression and torsion, where permanent stents may fracture, deform or complicate later treatment. The devices are used most extensively in the superficial femoral and popliteal arteries, while smaller-profile balloons are being developed for below-the-knee disease.

The U.S. peripheral category developed through successive product approvals beginning with Lutonix and IN.PACT Admiral in 2014, followed by additional platforms including Stellarex, Ranger, Chocolate Touch and SurVeil. This created a mature hospital-purchasing category with overlapping indications, multiple balloon diameters and lengths, and competition based on patency, deliverability, lesion coverage and supporting evidence.

Peripheral DCB revenue does not correspond directly to PAD prevalence. Commercial demand is generated when patients progress to symptomatic disease requiring angioplasty, repeat treatment or limb-preservation intervention. The diagnosed population therefore represents a substantially larger theoretical pool than the annually treated population.

 

U.S. Coronary Approval Created a New Conversion Market

The FDA approved Boston Scientific’s AGENT drug-coated balloon on February 29, 2024, making it the first coronary DCB approved in the United States. The device is indicated after appropriate vessel preparation for adults with coronary in-stent restenosis in reference-vessel diameters of 2.0–4.0 mm and lesions up to 26 mm in length.

Before approval, U.S. physicians treating coronary restenosis generally relied on repeat drug-eluting stenting or uncoated balloon angioplasty. AGENT therefore entered an established procedural pathway and created a conversion opportunity within existing percutaneous coronary intervention volumes rather than requiring hospitals to establish a new treatment infrastructure.

Coronary in-stent restenosis remains clinically relevant despite improvements in drug-eluting stents. Treatment for restenosis accounts for approximately 5%–10% of PCI procedures, with U.S. estimates approaching 10%. Another drug-eluting stent may produce a stent-within-a-stent structure that reduces lumen area and complicates future reintervention.

The AGENT IDE trial enrolled 600 patients at 40 U.S. centers. At one year, target-lesion failure occurred in 17.9% of patients treated with AGENT, compared with 28.6% of patients receiving an uncoated balloon. Ischemia-driven target-lesion revascularization and target-vessel myocardial infarction were also lower in the DCB group. The study established a superior alternative to plain balloon angioplasty for coronary restenosis rather than a universal replacement for contemporary drug-eluting stents.

Based on the reported 71.4% peripheral share, coronary DCBs represented the remaining directional 28.6% of the market, corresponding to approximately USD 343.2 million in 2025 and USD 599.7 million by 2032 at the overall market CAGR. Because coronary DCBs are identified as the faster-growing product category, a constant-share calculation may understate their eventual 2032 contribution.

 

Post-Approval Adoption Moves Coronary DCBs Into Routine U.S. Practice

Real-world evidence indicates that coronary DCBs entered U.S. practice rapidly after approval. Between April 2024 and June 2025, 14,946 coronary DCB procedures were recorded among 12,337 patients across 704 CathPCI Registry sites. Monthly DCB use increased from below 1% to 17.5% of eligible in-stent restenosis interventions.

The adoption pattern demonstrates the commercial advantage of entering an existing PCI workflow. Hospitals already possess guidewires, imaging systems, lesion-preparation balloons, antiplatelet protocols and interventional cardiology expertise. The principal purchasing change is the substitution of a coated balloon for an uncoated balloon or repeat stent in selected lesions.

Adoption is likely to remain uneven across hospitals. Successful DCB treatment depends on adequate lesion preparation, acceptable residual narrowing and the absence of severe recoil or flow-limiting dissection. Institutions with greater intravascular imaging use, complex-PCI experience and standardized restenosis pathways may adopt the devices faster than lower-volume centers.

The U.S. coronary segment also has a narrower approved label than the theoretical procedure opportunity. Physician interest extends to small-vessel, bifurcation and de novo disease, but these uses require stronger randomized evidence and broader regulatory authorization before becoming fully protected commercial markets.

 

Paclitaxel Remains the Established Standard

Paclitaxel remains the dominant drug used in established U.S. coronary and peripheral DCB portfolios. Its rapid tissue uptake allows a balloon to transfer an effective dose during a short period of vessel contact. Multiple approved devices, long-term registries and physician familiarity reinforce its commercial position.

The segment experienced a major challenge after a 2018 meta-analysis suggested a possible association between paclitaxel-coated peripheral devices and late mortality. The concern affected informed-consent discussions, purchasing decisions and physician confidence.

In July 2023, the FDA reviewed updated randomized trials, meta-analyses and large real-world datasets, including SWEDEPAD, VOYAGER PAD, German health-insurance data, U.S. Veterans Health Administration data and SAFE-PAD. The agency concluded that the totality of available evidence did not support an excess mortality risk from paclitaxel-coated devices.

The regulatory reassessment protected the category from a broad return to uncoated balloons. Competition consequently moved back toward primary patency, repeat-intervention reduction, catheter deliverability, lesion coverage and long-term clinical value.

Paclitaxel-coated devices account for most of the current commercial installed base, but the available market data do not provide a reliable standalone paclitaxel revenue share or segment CAGR that can be separated from the broader DCB market.

 

Sirolimus Establishes a Second Drug-Platform Segment

Sirolimus-coated balloons are creating a new competitive segment across peripheral and coronary intervention. Unlike paclitaxel, sirolimus is less naturally retained in vessel tissue after brief balloon contact. Manufacturers therefore use micro-reservoirs, phospholipid carriers, crystalline matrices and other delivery systems intended to sustain tissue exposure after the balloon is removed.

The 2026 SirPAD randomized trial materially strengthened the peripheral sirolimus evidence base. The study enrolled 1,252 patients with symptomatic infrainguinal artery disease. At one year, major adverse limb events occurred in 8.8% of patients receiving sirolimus-coated balloon treatment, compared with 15.0% after uncoated angioplasty. Adverse-event rates were broadly similar between the groups.

Cordis expanded the commercial segment by launching SELUTION SLR PTA in Japan in April 2026 as the country’s first approved sirolimus-eluting balloon for peripheral artery disease. Reported three-year outcomes included primary patency of 81.5% and freedom from reintervention of 93.8%.

Surmodics is pursuing a similar development route with the investigational Sundance sirolimus-coated balloon for below-the-knee disease. The 35-patient SWING study reported 71.4% primary patency at 24 months in the per-protocol population. The small study supports continued development but should not be treated as equivalent to a large randomized commercial dataset.

Sirolimus will not immediately displace paclitaxel. Paclitaxel platforms retain longer follow-up, multiple regulatory approvals and broad clinical familiarity. Sirolimus suppliers must demonstrate consistent coating integrity, tissue transfer, durable patency and dependable catheter performance across coronary, femoropopliteal and below-the-knee anatomies.

The sirolimus-coated segment is expected to expand faster than the overall 8.3% market CAGR because it begins from a small commercial base and is entering additional indications and geographies. The existing data, however, do not provide a reliable standalone sirolimus market share, revenue value or quantified segment CAGR.

 

De Novo Coronary Disease Remains an Evidence-Constrained Opportunity

De novo coronary disease represents a much larger theoretical procedure pool than in-stent restenosis, but current evidence does not support broad replacement of second-generation drug-eluting stents.

The REC-CAGEFREE I trial enrolled 2,272 patients with previously untreated, non-complex coronary lesions. At two years, device-oriented cardiovascular events occurred in 6.4% of patients treated with a DCB strategy, compared with 3.4% receiving a drug-eluting stent. The DCB strategy failed to demonstrate noninferiority and produced less favorable results overall. At three years, the corresponding event rates were 8.2% and 5.0%, with the difference driven mainly by repeat target-lesion treatment.

Outcomes appeared more comparable in vessels below approximately 3.0 mm, supporting continued development in small-vessel disease. In larger coronary vessels, the established mechanical support and drug delivery provided by a contemporary stent remain difficult to displace.

Coronary DCB expansion is therefore likely to remain indication-specific. Near-term commercial growth should be strongest in in-stent restenosis, selected small vessels and anatomies in which avoiding another permanent scaffold creates a clear clinical benefit.

The de novo coronary segment may become commercially significant if ongoing trials establish reliable patient-selection criteria and obtain broader regulatory labels. Existing evidence does not support applying the full de novo PCI population to a current DCB revenue forecast.

 

Vessel Preparation Determines Clinical and Commercial Performance

Drug-coated balloons do not independently correct every component of vascular disease. Calcification, fibrotic plaque, underexpanded stents and severe lesion resistance can prevent adequate balloon expansion and reduce drug transfer.

Procedures may require predilation with conventional, non-compliant, scoring or cutting balloons. Peripheral lesions may also require atherectomy or intravascular lithotripsy, while coronary procedures increasingly use intravascular ultrasound or optical coherence tomography to identify stent underexpansion and define lesion morphology.

Severe recoil or a flow-limiting dissection may still require bailout stenting after balloon treatment. DCB use therefore reduces permanent-implant exposure but does not eliminate stent demand.

This procedural dependency expands the economic value surrounding each DCB case. Manufacturers with complementary lesion-preparation products, imaging relationships, physician-training programs and broad catheter portfolios may capture more value than companies competing through the balloon coating alone.

The available content does not provide a reliable standalone revenue share or CAGR for vessel-preparation devices used specifically with DCB procedures.

 

Hospitals Lead End-User Revenue While Ambulatory Centers Gain Share

Hospitals accounted for approximately 68.3% of global DCB catheter revenue in 2025. Applying this share directionally to the total market produces a hospital end-user allocation of approximately USD 819.6 million in 2025 and USD 1.43 billion by 2032 at the overall market CAGR.

Hospitals retain the strongest position because they manage complex coronary PCI, chronic limb-threatening ischemia, intravascular imaging, emergency complications, surgical backup and multidisciplinary cardiovascular care. They also control formulary evaluation and high-volume device contracting.

Ambulatory surgical centers and office-based laboratories are expected to expand faster, particularly in elective peripheral intervention. Their purchasing priorities may place greater emphasis on procedure time, device standardization, predictable reimbursement and avoidance of repeat hospitalization.

Migration to ambulatory settings will remain procedure-specific. Complex coronary restenosis, heavily calcified disease, unstable patients and interventions with a greater likelihood of bailout treatment are more likely to remain in hospital-based catheterization laboratories.

The available market data identify ambulatory facilities as a faster-growing end-user category but do not provide a reliable standalone revenue value, share or CAGR for the segment.

 

Europe and Japan Provide Mature Reference Markets

European clinicians gained access to coronary DCBs earlier than U.S. physicians, producing deeper familiarity with balloon-only treatment. European guidance historically gave DCB treatment a strong recommendation for coronary restenosis, although more recent guidance has become increasingly selective when comparing DCBs with contemporary drug-eluting stents in drug-eluting-stent restenosis.

U.K. national audit data covering April through September 2025 showed that drug-eluting balloons were used in just over 40% of restenosis lesions. Penetration was relatively stable compared with the preceding reporting period, indicating that DCBs have become an established treatment option rather than a newly introduced technology.

Japan also represents a mature coronary DCB market, with established use in restenosis and small coronary vessels. The April 2026 launch of SELUTION SLR PTA additionally turned Japan into an important commercial reference market for peripheral sirolimus-coated technology.

These markets provide manufacturers with long-term clinical experience, post-market data and procurement evidence that may support expansion into newer geographies. However, local reimbursement, tendering practices and regulatory labels prevent European or Japanese penetration rates from being transferred directly to the U.S. market.

 

North America Leads Revenue While Asia-Pacific Expands Faster

North America accounted for approximately 44.2% of global DCB catheter revenue in 2025. Applying this share directionally to the USD 1.2 billion market produces an estimated regional allocation of USD 530.4 million in 2025 and approximately USD 926.8 million by 2032, assuming growth in line with the global CAGR.

The region benefits from high PCI volumes, established peripheral-intervention infrastructure, specialist cardiovascular centers, broad use of advanced imaging and the introduction of the first FDA-approved coronary DCB.

U.S. coronary adoption should increase North America’s near-term value, although reimbursement, hospital contracting and the narrow restenosis label will influence the speed of conversion from repeat stenting and uncoated angioplasty.

Asia-Pacific is identified as the fastest-growing regional market. Expansion is supported by large cardiovascular patient populations, rising catheterization capacity, established coronary DCB use in Japan and the introduction of sirolimus-based peripheral platforms. The available content does not provide a reliable standalone Asia-Pacific CAGR or 2032 revenue value.

 

Analyst Perspective: New Platforms Must Compete With Both Stents and Established DCBs

The principal commercial challenge is not the absence of effective vascular devices. Contemporary drug-eluting stents provide strong outcomes in most de novo coronary lesions, while established paclitaxel-coated balloons already offer durable treatment in peripheral disease and coronary restenosis.

New DCB platforms must demonstrate a clear advantage in repeat-intervention reduction, small-vessel treatment, long-lesion durability, vessel healing, deliverability or avoidance of additional metal layers. A novel coating mechanism alone is unlikely to support premium pricing without dependable drug transfer and long-term clinical evidence.

Paclitaxel should retain as the standard because of its regulatory breadth, physician familiarity and accumulated follow-up. Sirolimus-coated devices represent the strongest emerging competitive segment, particularly as randomized peripheral evidence and new commercial approvals reduce uncertainty around sustained drug delivery.

Coronary growth will be driven primarily by conversion within in-stent restenosis rather than immediate replacement of drug-eluting stents in the wider de novo market. Peripheral growth will depend on lesion-specific durability, below-the-knee evidence and the ability to reduce reintervention in complex disease.

 

Drug-Coated Balloon Catheter Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.30 Billion
Revenue Forecast in 2032	USD 2.65 Billion
Overall Growth Rate	CAGR of 10.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Paclitaxel-Coated Balloon Catheters, Sirolimus-Coated Balloon Catheters
By Application	Peripheral Artery Disease, Coronary In-Stent Restenosis, Small-Vessel Coronary Disease, De Novo Coronary Lesions, Below-the-Knee Artery Disease, Arteriovenous Fistula Stenosis
By End User	Hospitals, Cardiac Catheterization Laboratories, Vascular Intervention Centres, Ambulatory Surgical Centres, Office-Based Laboratories
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising peripheral artery disease burden, increasing coronary in-stent restenosis treatment demand, FDA approval of coronary drug-coated balloons, growing preference for implant-free vascular intervention, expansion of sirolimus-coated balloon technologies, and increasing adoption of minimally invasive endovascular procedures
Customization Option	Available upon request